These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12685055)

  • 1. Heparin and low molecular weight heparin: background and pharmacology.
    Morris TA
    Clin Chest Med; 2003 Mar; 24(1):39-47. PubMed ID: 12685055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparins: background and pharmacology.
    Morris TA
    Semin Respir Crit Care Med; 2000; 21(6):537-46. PubMed ID: 16088762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
    Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
    Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis?
    Boneu B
    Thromb Res; 2000 Oct; 100(2):V113-20. PubMed ID: 11053624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalteparin: a low-molecular-weight heparin.
    Howard PA
    Ann Pharmacother; 1997 Feb; 31(2):192-203. PubMed ID: 9034422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Heparins].
    Marbet GA
    Ther Umsch; 2003 Jan; 60(1):10-3. PubMed ID: 12638471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C; Casali G; Vitali L
    Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis.
    Carelli G; Maffei FH; Mattar L; Ferrari IC; Thomazini-Santos IA; de Carvalho LR
    Pathophysiol Haemost Thromb; 2005; 34(6):263-8. PubMed ID: 16772737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy?
    Andrassy K; Eschenfelder V
    Thromb Res; 1996; 81(2 Suppl):S29-38. PubMed ID: 8822125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic activity and its relationship to in vitro anticoagulant effects.
    Gray E; Padilla A; Barrowcliffe TW
    Haemostasis; 1993 Mar; 23 Suppl 1():99-102. PubMed ID: 8388358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing and monitoring of low-molecular-weight heparins in special populations.
    Duplaga BA; Rivers CW; Nutescu E
    Pharmacotherapy; 2001 Feb; 21(2):218-34. PubMed ID: 11213859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
    Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
    Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans.
    Frydman A
    Haemostasis; 1996; 26 Suppl 2():24-38. PubMed ID: 8707165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New data on the pharmacology of heparin and low molecular weight heparins.
    Samama MM; Bara L; Gouin-Thibault I
    Drugs; 1996; 52 Suppl 7():8-14; discussion 14-5. PubMed ID: 9042555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbit.
    Amar J; Caranobe C; Sie P; Boneu B
    Br J Haematol; 1990 Sep; 76(1):94-100. PubMed ID: 2223652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
    Hiebert LM
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of LMWHs.
    Samama MM; Gerotziafas GT
    Semin Thromb Hemost; 2000; 26 Suppl 1():31-8. PubMed ID: 11011804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of thrombotic and cardiovascular disorders in the new millenium.
    Fareed J; Hoppensteadt DA; Bick RL
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of low molecular weight heparins in animal models.
    Fareed J; Fu K; Yang LH; Hoppensteadt DA
    Semin Thromb Hemost; 1999; 25 Suppl 3():51-5. PubMed ID: 10549716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.